Oscar Wong/Moment via Getty Images Pfizer (NYSE:PFE) stock is an increasingly popular option for dividend growth investors due to its 14-year dividend growth streak, strong balance sheet, 6% yield, and what appears to be a deeply discounted stock price after the stock's brutal sell-off over the past two years: Data by YCharts However, I do not believe that PFE is attractive enough to warrant buying at this point, and in this article, I explain why. The Bull Case For PFE Stock Despite facing a challengi ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this drugmaker have returned -0.8%, compared to the Zacks S&P 500 composite's +0.9% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Pfizer falls in, has gained 7.1%. The key question now is: What could be the stock's future direction?Although media reports ...

Michael M. Santiago It's one thing to find a cheaply valued company and another thing to identify a lucrative investment opportunity. Pfizer Inc. (PFE) has been cheap for some time now, with the pharmaceutical giant suffering from lackluster growth in the post-pandemic era with the positive financial impact of Comirnaty and Paxlovid waning. Last November, I found Pfizer cheaply valued, but I failed to identify a catalyst that could drive PFE stock higher in the foreseeable future. In my previous article, af ...

In trading on Wednesday, shares of Pfizer were yielding above the 6% mark based on its quarterly dividend (annualized to $1.68), with the stock changing hands as low as $27.93 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the S&P 500 ETF (SPY back on 12/31/1999 — you would have paid $146.88 per share. Fast forw ...

The latest trading session saw Pfizer (PFE) ending at $28.32, denoting a -1.32% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.37%. Elsewhere, the Dow lost 0.62%, while the tech-heavy Nasdaq lost 0.19%.Prior to today's trading, shares of the drugmaker had gained 6.06% over the past month. This has outpaced the Medical sector's gain of 4.61% and the S&P 500's gain of 1.56% in that time.The upcoming earnings release of Pfizer will be of great interest t ...

DAVOS, Switzerland—Albert Bourla has ambitious plans to turn around the situation at Pfizer. The market will decide if talk is cheap, but at least for now the stock looks cheap, or so the biopharma CEO wants investors to believe. And he put his money where his mouth is. ...

One of the most important companies during the peak of the COVID-19 pandemic was pharmaceutical giant Pfizer (PFE 1.06%). The company's breakthrough vaccine helped pave the way for a post-pandemic world. Over the last couple of years, demand for Pfizer's COVID-19 treatments helped spur record-breaking revenue.However, as pandemic concerns wane, some investors may wonder where Pfizer's next growth engine lies. While the company has several catalysts identified, I have my doubts on their prospects. And I'm no ...

Last year wasn't a particularly good one for Pfizer (PFE 1.06%). Even CEO Albert Bourla says so. "We missed our internal projections and also, we missed the expectations of The Street... And clearly, that was shown in our stock price performance, that was very, very bad," Bourla said at the JPMorgan Healthcare Conference last week.In October, the big pharma company slashed its forecasts for annual coronavirus vaccine and treatment sales due to lower-than-expected demand and announced a cost realignment plan ...

JHVEPhoto Pfizer Inc. (NYSE:PFE) stock has continued to reel from the exhaustion of COVID dollars. Specifically, the 2023 downturn has been primarily dragged by a faster-than-expected normalization of Comirnaty vaccine and Paxlovid COVID treatment uptakes. In addition to the $5.6 billion write-off on Paxlovid/Comirnaty inventory in Q3, management has also provided a weaker-than-expected guidance for said products in 2024. Specifically, management guides $8 billion in Comirnaty/Paxlovid revenue for 2024, und ...

Post-pandemic, the global bio-pharmaceutical sector, often overlooked, presents undervalued opportunities, notably in blue-chip stocks like Pfizer (NYSE:PFE). Following a 42% correction in the past year, PFE stock, with a 5.84% dividend yield, appears promising for 2024. The company anticipates $60 billion in revenue, signaling 9% year-on-year growth, supported by a compelling product pipeline.Here are some more reasons why investing in PFE stock will bring you to ultimate highs in 2024.The Excellent Bull C ...